109 related articles for article (PubMed ID: 17874223)
1. Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.
Twaites B; Wilton LV; Layton D; Shakir SA
Acta Diabetol; 2007 Dec; 44(4):233-9. PubMed ID: 17874223
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study.
Marshall V; Wilton L; Shakir S
Acta Diabetol; 2006 May; 43(1):6-13. PubMed ID: 16710643
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of orlistat: results of a prescription-event monitoring study.
Acharya NV; Wilton LV; Shakir SA
Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
[TBL] [Abstract][Full Text] [Related]
4. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
Perrio MJ; Wilton LV; Shakir SA
Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
Schatz H; Schoppel K; Lehwalder D; Schandry R
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):262-6. PubMed ID: 12951631
[TBL] [Abstract][Full Text] [Related]
6. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
Biswas PN; Wilton LV; Shakir SW
J Hum Hypertens; 2002 Nov; 16(11):795-803. PubMed ID: 12444541
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
Buggy Y; Layton D; Fogg C; Shakir SA
Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
[TBL] [Abstract][Full Text] [Related]
8. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
[TBL] [Abstract][Full Text] [Related]
9. A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring.
Perrio MJ; Wilton LV; Shakir SA
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):969-78. PubMed ID: 17476703
[TBL] [Abstract][Full Text] [Related]
10. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England.
Twaites BR; Wilton LV; Shakir SA
J Psychopharmacol; 2007 Jun; 21(4):392-9. PubMed ID: 17656426
[TBL] [Abstract][Full Text] [Related]
11. The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients.
Hazell L; Cornelius V; Wilton LV; Shakir SA
BJU Int; 2009 Feb; 103(4):506-14. PubMed ID: 18990133
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999.
Boshier A; Wilton LV; Shakir SA
BJU Int; 2004 Apr; 93(6):796-801. PubMed ID: 15049992
[TBL] [Abstract][Full Text] [Related]
13. Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction.
Maclennan KM; Boshier A; Wilton LV; Shakir SA
BJU Int; 2006 Jul; 98(1):125-31. PubMed ID: 16831156
[TBL] [Abstract][Full Text] [Related]
14. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Vlckova V; Cornelius V; Kasliwal R; Wilton L; Shakir SA
Drug Saf; 2009; 32(5):409-18. PubMed ID: 19419235
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study.
Layton D; Clarke A; Wilton LV; Shakir SA
Osteoporos Int; 2005 May; 16(5):490-500. PubMed ID: 15309382
[TBL] [Abstract][Full Text] [Related]
16. Nateglinide (Starlix): update on a new antidiabetic agent.
Phillips LS; Dunning BE
Int J Clin Pract; 2003; 57(6):535-41. PubMed ID: 12918894
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.
Kasliwal R; Wilton LV; Shakir SA
Drug Saf; 2008; 31(10):839-50. PubMed ID: 18759508
[TBL] [Abstract][Full Text] [Related]
18. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography.
Bengel FM; Abletshauser C; Neverve J; Schnell O; Nekolla SG; Standl E; Schwaiger M
Diabet Med; 2005 Feb; 22(2):158-63. PubMed ID: 15660732
[TBL] [Abstract][Full Text] [Related]
19. An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease.
Hazell L; Boshier A; Harris S; Wilton LV; Shakir SA
BJU Int; 2007 Feb; 99(2):387-93. PubMed ID: 17313426
[TBL] [Abstract][Full Text] [Related]
20. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes.
Morita Y; Ueno T; Sasaki N; Tateishi Y; Nagata E; Kage M; Sata M
Hepatogastroenterology; 2005; 52(65):1338-43. PubMed ID: 16201069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
